Alfonso Ielasi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5258895/publications.pdf

Version: 2024-02-01

216 papers	4,281 citations	147801 31 h-index	138484 58 g-index
251 all docs	251 docs citations	251 times ranked	4717 citing authors

#	Article	IF	Citations
1	Safety and efficacy of systematic lesion preparation with a novel generation scoring balloon in complex percutaneous interventions: results from a prospective registry. Minerva Cardiology and Angiology, 2023, 70, .	0.7	2
2	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. Cardiovascular Revascularization Medicine, 2022, 35, 66-73.	0.8	3
3	â€œRotaTripsyâ€•for Severe Calcified Coronary Artery Lesions: Insights From a Real-World Multicenter Cohort. Cardiovascular Revascularization Medicine, 2022, 37, 78-81.	0.8	11
4	Optical coherence tomography, intravascular ultrasound or angiography guidance for distal left main coronary stenting. The <scp>ROCK</scp> cohort <scp>II</scp> study. Catheterization and Cardiovascular Interventions, 2022, 99, 664-673.	1.7	20
5	The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. Cardiovascular Revascularization Medicine, 2022, 39, 106-113.	0.8	5
6	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. International Journal of Cardiology, 2022, 349, 31-38.	1.7	4
7	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. Journal of Cardiovascular Medicine, 2022, 23, 278-280.	1.5	1
8	An Update on New Generation Transcatheter Aortic Valves and Delivery Systems. Journal of Clinical Medicine, 2022, 11, 499.	2.4	12
9	Trans-Catheter Valve-in-Valve Implantation for the Treatment of Aortic Bioprosthetic Valve Failure. Journal of Clinical Medicine, 2022, 11, 344.	2.4	2
10	Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosisâ€”A Multicenter Real-World Experience. Journal of Clinical Medicine, 2022, 11, 443.	2.4	14
11	Management and Outcome of FailedÂPercutaneous Edge-to-Edge MitralÂValveÂPlasty. JACC: Cardiovascular Interventions, 2022, 15, 411-422.	2.9	7
12	Clinical Comparison of a Novel Balloon-Expandable Versus a Self-Expanding Transcatheter Heart Valve for the Treatment of Patients with Severe Aortic Valve Stenosis: The EVAL Registry. Journal of Clinical Medicine, 2022, 11, 959.	2.4	12
13	CRT-700.31 Implantation of Contemporary Transcatheter Aortic Valves in Small Aortic Annuli: The International Multicenter TAVI-SMALL 2 Registry. JACC: Cardiovascular Interventions, 2022, 15, S63-S64.	2.9	0
14	Balloon aortic valvuloplasty review: the revenge during COVID-19 outbreak?. Minerva Cardiology and Angiology, 2022, , .	0.7	0
15	Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study. EuroIntervention, 2022, 17, e1397-e1406.	3.2	21
16	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. Journal of Clinical Medicine, 2022, 11, 2926.	2.4	3
17	Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. JACC: Cardiovascular Interventions, 2022, 15, 1543-1554.	2.9	12
18	A HYbrid APproach Evaluating a DRug-Coated Balloon in Combination With a New-Generation Drug-Eluting Stent in the Treatment of De Novo Diffuse Coronary Artery Disease: The HYPER Pilot Study. Cardiovascular Revascularization Medicine, 2021, 28, 14-19.	0.8	10

#	Article	IF	Citations
19	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. Cardiovascular Revascularization Medicine, 2021, 30, 1-8.	0.8	1
20	Intravascular lithotripsy in calcifiedâ€coronary lesions: A realâ€world observational, European multicenter study. Catheterization and Cardiovascular Interventions, 2021, 98, 225-235.	1.7	20
21	Transcatheter Valve-in-Valve Implantation With a Novel Balloon-Expandable Device in Patients With Bioprosthetic Heart Valve Failure: A Case Series. Cardiovascular Revascularization Medicine, 2021, 28, 98-101.	0.8	6
22	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 411-420.	1.7	6
23	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	2.0	21
24	MyVal and Mini-Chimney Stenting to Prevent Coronary Obstruction During Full Root Stent-Less Aortic Valve-In-Valve Procedure. Cardiovascular Revascularization Medicine, 2021, 22, 122-123.	0.8	2
25	Usefulness of Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris. American Journal of Cardiology, 2021, 139, 22-27.	1.6	15
26	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. International Journal of Cardiology, 2021, 325, 109-114.	1.7	19
27	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	2.9	30
28	Quantitative Angiographic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Implantation among Three Balloon-Expandable Valves. Global Heart, 2021, 16, 20.	2.3	21
29	Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Clinical Research in Cardiology, 2021, 110, 667-675.	3.3	8
30	Results of paclitaxel-drug-coated balloons (Pantera Lux) for coronary in-stent restenosis: Italian experience from REGistry of Paclitaxel Eluting Balloon in ISR study. Journal of Cardiovascular Medicine, 2021, 22, 469-477.	1.5	2
31	Incidence, Management, Immediate and Long-Term Outcome of Guidewire and Device Related Grade III Coronary Perforations (from G3CAP - Cardiogroup VI Registry). American Journal of Cardiology, 2021, 143, 37-45.	1.6	8
32	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1165-1178.	2.8	32
33	Percutaneous mechanical circulatory support from the collaborative multicenter Mechanical Unusual Support in <scp>TAVI</scp> (<scp>MUST</scp>) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E862-E869.	1.7	9
34	Snaring the Transcatheter Heart Valve Delivery System During Aortic Valve Replacement: When and Why. Cardiovascular Revascularization Medicine, 2021, 28, 81-84.	0.8	2
35	Successful Percutaneous Closure of an Iatrogenic Ventricular Septal Defect Following TAVR With the ACURATE neo2. JACC: Cardiovascular Interventions, 2021, 14, e173-e176.	2.9	0
36	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. PLoS ONE, 2021, 16, e0255263.	2.5	12

#	Article	IF	Citations
37	Type A aortic dissection after transcatheter aortic valve replacement: is a surgical approach always needed?. Journal of Cardiovascular Medicine, 2021, 22, e29-e31.	1.5	1
38	Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2021, 6, 936.	6.1	7
39	Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study. International Journal of Cardiology, 2021, 337, 29-37.	1.7	12
40	Assessing the Impact of Transcatheter Aortic Valve Implantation on Cardiac Catheterisation: A Multicentric Study. Heart Lung and Circulation, 2021, 30, 1397-1405.	0.4	3
41	Transcatheter Replacement of Transcatheter Versus Surgically Implanted AorticÂValveÂBioprostheses. Journal of the American College of Cardiology, 2021, 77, 1-14.	2.8	64
42	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. Journal of Cardiovascular Medicine, 2021, 22, 94-100.	1.5	29
43	Back to the future: the role of DCB for the treatment of coronary bifurcation. Reviews in Cardiovascular Medicine, 2021, 22, 1421.	1.4	5
44	299â€ƒ3-Year results of STEMI patients treated with a pre-specified BVS implantation strategy: BVS SYTEMI strategy-it long term. European Heart Journal Supplements, 2021, 23, .	0.1	0
45	90â€ƒAnnular size and interaction with trans-catheter aortic valves for the treatment of severe bicuspid aortic valve stenosis: insights from the beat registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
46	680â€ƒPeripheral intravascular lithotripsy of ILEO-femoral arteries to facilitate transfemoral TAVI: a multicentric prospective registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
47	692â€ƒImpact of COVID-19 pandemic on in-hospital outcomes for patients with acute coronary syndrome: a propensity-weighted, multicentre study. European Heart Journal Supplements, 2021, 23, .	0.1	1
48	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 32-40.	4.0	15
49	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	1.7	3
50	Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). International Journal of Cardiology, 2020, 299, 49-55.	1.7	46
51	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). Catheterization and Cardiovascular Interventions, 2020, 96, 255-265.	1.7	4
52	â€œRota-Tripsyâ€: A Successful Combined Approach for the Treatment of a Long and Heavily Calcified Coronary Lesion. Cardiovascular Revascularization Medicine, 2020, 21, 152-154.	0.8	13
53	TCT CONNECT-7 Everolimus-Eluting Stent Versus Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction: 10-Year Follow-Up of the Multicenter Randomized Controlled Examination Trial. Journal of the American College of Cardiology, 2020, 76, B4.	2.8	2
54	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. Cardiology Clinics, 2020, 38, 575-588.	2.2	5

#	Article	IF	Citations
55	Multimodal Imaging of Post-Stenting Mycotic Coronary Pseudoaneurysm Complicated by Device Fracture and Myocardial Abscess. JACC: Case Reports, 2020, 2, 1667-1670.	0.6	3
56	Editorial: Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. Frontiers in Cardiovascular Medicine, 2020, 7, 581109.	2.4	0
57	SARS-CoV-2 Aiming for the Heart: A Multicenter Italian Perspective About Cardiovascular Issues in COVID-19. Frontiers in Physiology, 2020, 11, 571367.	2.8	12
58	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. Journal of the American College of Cardiology, 2020, 75, 1882-1893.	2.8	140
59	Outcome of Coronary Ostial Stenting to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009017.	3.9	6
60	Balloon Versus Self-Expandable Valve for the Treatment of Bicuspid Aortic Valve Stenosis. Circulation: Cardiovascular Interventions, 2020, 13, e008714.	3.9	62
61	IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 1555-1559.	0.8	37
62	Dual antiplatelet therapy prolongation in high-risk patients with prior myocardial infarction: insights from the post-PCI registry. Journal of Cardiovascular Medicine, 2020, 21, 603-609.	1.5	2
63	Realâ€world reasons and outcomes for 1â€month versus longer dual antiplatelet therapy strategies with a polymerâ€free BIOLIMUS A9â€coated stent. Catheterization and Cardiovascular Interventions, 2020, 96, E248-E256.	1.7	1
64	ST-Elevation Myocardial Infarction in Patients With COVID-19. Circulation, 2020, 141, 2113-2116.	1.6	376
65	Latest generation stents: is it time to revive the bioresorbable scaffold?. Minerva Cardioangiologica, 2020, 68, 415-435.	1.2	2
66	Dual antiplatelet therapy strategies and clinical outcomes in patients treated with polymer-free biolimus A9-coated stents. EuroIntervention, 2020, 15, e1358-e1365.	3.2	5
67	â€œShock-Pellaâ€• Combined management of an undilatable ostial left circumflex stenosis in a complex high-risk interventional procedure patient. Cardiology Journal, 2020, 27, 427-428.	1.2	2
68	Intracoronary lithoplasty-facilitated expansion of an undilatable intra-stent lesion. AsiaIntervention, 2020, 6, 58-59.	0.4	0
69	Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction. Journal of Cardiovascular Medicine, 2020, 21, 825-828.	1.5	0
70	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis treated with transcatheter valve replacement: insights from the BEAT international collaborative registry. European Heart Journal, 2020, 41, .	2.2	2
71	Complications Following Percutaneous Mitral Valve Repair. Frontiers in Cardiovascular Medicine, 2019, 6, 146.	2.4	27
72	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 2079-2088.	2.9	103

#	Article	IF	Citations
73	Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients. IJC Heart and Vasculature, 2019, 23, 100375.	1.1	11
74	Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. Cardiology, 2019, 142, 93-96.	1.4	11
75	Oneâ€year clinical outcome of biodegradable polymer sirolimusâ€eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 972-979.	1.7	5
76	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		6
77	P2820Contemporary indications, dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent: the all-comers FREEDOM registry. European Heart Journal, 2019, 40, .	2.2	0
78	P2794Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free biolimus A9-coated stent: insights from the all-comers FREEDOM registry. European Heart Journal, 2019, 40, .	2.2	0
79	P2801Hard events after orsiro sirolimus-eluting stent (HEROES) in STEMI: a multicenter registry. European Heart Journal, 2019, 40, .	2.2	0
80	P5531A systematic follow-up strategy after percutaneous coronary intervention based on patient risk profile: the prospective POST-PCI registry. European Heart Journal, 2019, 40, .	2.2	0
81	Oneâ€year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 404-410.	1.7	1
82	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). Cardiovascular Revascularization Medicine, 2019, 20, 700-704.	0.8	6
83	Pulmonary embolism with migrating thrombus through patent foramen ovale: A case for a mixed pharmacological and percutaneous management. Journal of Cardiology Cases, 2019, 19, 19-21.	0.5	7
84	Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study. EuroIntervention, 2019, 15, 108-115.	3.2	4
85	Recurrent and life-threatening strokes after pacemaker implantation in a patient affected by concealed superior sinus venosus atrial septal defect. Cardiology Journal, 2019, 26, 300-301.	1.2	0
86	The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions. Egyptian Heart Journal, 2019, 71, 31.	1.2	2
87	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). International Journal of Cardiology, 2018, 260, 36-41.	1.7	15
88	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segmentâ€"Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
89	Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry). International Journal of Cardiology, 2018, 258, 50-54.	1.7	6
90	Bioresorbable Vascular Scaffolds in In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 220-221.	2.9	1

#	Article	IF	Citations
91	Bioresorbable vascular scaffold versus everolimusâ€eluting stents or drug eluting balloon for the treatment of coronary inâ€stent restenosis: 1â€Year followâ€up of a propensity score matching comparison (the BIORESOLVEâ€ISR Study). Catheterization and Cardiovascular Interventions, 2018, 92, 668-677.	1.7	6
92	Absorb bioresorbable vascular scaffold vs. everolimusâ€eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTADâ€ABSORB studies. Catheterization and Cardiovascular Interventions, 2018, 92, E115-E124.	1.7	6
93	Hybrid coronary revascularization versus percutaneous strategies in left main stenosis: a propensity match study. Journal of Cardiovascular Medicine, 2018, 19, 253-260.	1.5	9
94	Transradial versus transfemoral ancillary approach in complex structural, coronary, and peripheral interventions. Results from the multicenter ancillary registry: A study of the Italian Radial Club. Catheterization and Cardiovascular Interventions, 2018, 91, 97-102.	1.7	15
95	Clinical outcomes of overlapping versus nonâ€overlapping everolimusâ€eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	7
96	TCT-353 Acute and mid-term performance of Magmaris Bioresorbable Scaffold implantation in complex lesions: a multicenter experience.. Journal of the American College of Cardiology, 2018, 72, B144.	2.8	0
97	P6378A polymer-free biolimus-coated stent for the management of real-world high bleeding risk patients with coronary artery disease. European Heart Journal, 2018, 39, .	2.2	0
98	TCT-704 Feasibility of overlapped Magnesium-made bioresorbable scaffold implantation in long lesions: results from the multicenter italian registry (MAGIC). Journal of the American College of Cardiology, 2018, 72, B281-B282.	2.8	0
99	Acute and longâ€term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations: Insights from G3â€CAP registry. Catheterization and Cardiovascular Interventions, 2018, 92, 1247-1255.	1.7	20
100	Safety of FFR-guided revascularisation deferral in Anatomically prognostiC diseasE (FACE:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td 270, 107-112.	1.7	15
101	One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI) Tj ETQq1 1 0.784314 rgBT /Overlock	3.2	5
102	A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions. Cardiovascular Revascularization Medicine, 2017, 18, S4-S9.	0.8	1
103	In-Hospital and 1-Year Outcomes of Rotational Atherectomy and Stent Implantation in Patients With Severely Calcified Unprotected Left Main Narrowings (from the Multicenter ROTATE Registry). American Journal of Cardiology, 2017, 119, 1331-1337.	1.6	19
104	CRT-100.78 A Hybrid Strategy With Bioresorbable Vascular Scaffolds And Drug Eluting Stents For Treating Complex Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, S25.	2.9	0
105	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	2.9	1
106	Rationale and design of a multicenter, international and collaborative Coronary Artery Aneurysm Registry (<scp>CAAR</scp>). Clinical Cardiology, 2017, 40, 580-585.	1.8	8
107	Final shape of biovascular scaffolds and clinical outcome. Results from a multicenter all-comers study with intravascular imaging. International Journal of Cardiology, 2017, 228, 209-213.	1.7	1
108	Mechanisms of Very Late BioresorbableÂScaffold Thrombosis. Journal of the American College of Cardiology, 2017, 70, 2330-2344.	2.8	117

#	Article	IF	Citations
109	Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	10
110	First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1901-1903.	2.9	33
111	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 1855-1864.	2.9	22
112	Management of diabetic patients hospitalized for acute coronary syndromes. Journal of Cardiovascular Medicine, 2017, 18, 572-579.	1.5	2
113	TCTAP A-059 Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary in Stent Restenosis: Long-term Clinical Outcomes of a Multicenter Italian Experience. Journal of the American College of Cardiology, 2017, 69, S31.	2.8	0
114	TCTAP C-080 First-in-man Demonstration of Complete Bioresorbable Vascular Scaffold Resorption After Treatment of In-stent Restenosis. Journal of the American College of Cardiology, 2017, 69, S169-S170.	2.8	0
115	Sustained Reduction of Tricuspid Regurgitation After Percutaneous Repair With the MitraClip System in a Patient With a Dual Chamber Pacemaker. JACC: Cardiovascular Interventions, 2017, 10, e147-e149.	2.9	6
116	First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis. Coronary Artery Disease, 2017, 28, 437-439.	0.7	1
117	A prospective evaluation of a standardized strategy for the use of a polymeric everolimusâ€eluting bioresorbable scaffold in STâ€segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGYâ€T study. Catheterization and Cardiovascular Interventions, 2017, 89, 1129-1138.	1.7	9
118	Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?. Journal of Thoracic Disease, 2017, 9, S969-S978.	1.4	10
119	Bioresorbable coronary scaffolds in 2017. Journal of Thoracic Disease, 2017, 9, S886-S886.	1.4	0
120	The impact of the 3-year ABSORB II trial results on my clinical practice: an Italian survey. Journal of Thoracic Disease, 2017, 9, S898-S902.	1.4	0
121	Bioresorbable scaffolds and drug-eluting balloons for the management of spontaneous coronary artery dissections. Journal of Thoracic Disease, 2016, 8, E1328-E1330.	1.4	11
122	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multiâ€center registry. Catheterization and Cardiovascular Interventions, 2016, 88, 881-889.	1.7	38
123	TCT-417 Bioresorbable vascular scaffold in chronic total coronary artery occlusions: results from the RAI registry. Journal of the American College of Cardiology, 2016, 68, B168-B169.	2.8	0
124	TCT-425 Bioresorbable vascular scaffold technology for small vessel coronary artery disease: results from the Italian multicenter RAI Registry. Journal of the American College of Cardiology, 2016, 68, B171-B172.	2.8	2
125	Coronary Sinus Reducer systemâ„¢: A new therapeutic option in refractory angina patients unsuitable for revascularization. International Journal of Cardiology, 2016, 209, 122-130.	1.7	16
126	Sealing spontaneous coronary artery dissection with bioresorbable vascular scaffold implantation: Data from the prospective â€œRegistro Absorb Italianoâ€•(RAI Registry). International Journal of Cardiology, 2016, 212, 44-46.	1.7	26

#	Article	IF	Citations
127	An unusual case of cardiogenic shock late following surgical aortic valve replacement. Journal of Cardiology Cases, 2016, 13, 162-164.	0.5	2
128	Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis. Circulation: Cardiovascular Interventions, 2016, 9, e003148.	3.9	33
129	Rotational atherectomy in very long lesions: Results for the ROTATE registry. Catheterization and Cardiovascular Interventions, 2016, 88, E164-E172.	1.7	39
130	Bioresorbable vascular scaffolds for small vessels coronary disease: The BVSâ€ssave registry. Catheterization and Cardiovascular Interventions, 2016, 88, 380-387.	1.7	12
131	Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). International Journal of Cardiology, 2016, 208, 40-45.	1.7	32
132	Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. Journal of Atrial Fibrillation, 2016, 9, 1509.	0.5	3
133	ROTational AThErectomy in acute coronary syndrome: early and midterm outcomes from a multicentre registry. EuroIntervention, 2016, 12, 1457-1464.	3.2	43
134	In-hospital and midterm clinical outcomes of rotational atherectomy followed by stent implantation: the ROTATE multicentre registry. EuroIntervention, 2016, 12, 1448-1456.	3.2	49
135	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the â€œno more metallic cagesâ€•multicentre pilot experience. EuroIntervention, 2016, 11, e1589-e1595.	3.2	13
136	TCT-430 Ancillary radial versus femoral/brachial approach to reduce vascular complications in complex coronary, peripheral and structural interventions. Preliminary results of a study from the Italian Radial Club. Journal of the American College of Cardiology, 2015, 66, B175-B176.	2.8	2
137	Clinical outcomes of realâ€world patients treated with an amphilimus polymerâ€free stent versus new generation everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
138	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Medical Devices: Evidence and Research, 2015, 8, 317.	0.8	5
139	Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorbâ„¢ BVS: study design. Cardiovascular Revascularization Medicine, 2015, 16, 340-343.	0.8	12
140	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	1.7	34
141	Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre â€œRegistro ABSORB Italianoâ€•(RAI registry). EuroIntervention, 2015, 11, 157-162.	3.2	46
142	Very late bioresorbable vascular scaffold thrombosis due to late device recoil. International Journal of Cardiology, 2015, 189, 132-133.	1.7	9
143	Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. American Journal of Cardiology, 2015, 116, 705-710.	1.6	36
144	Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection. American Journal of Cardiology, 2015, 116, 66-73.	1.6	230

#	Article	IF	Citations
145	Incidence, Management, and Immediate- and Long-Term Outcomes After Iatrogenic Aortic Dissection During Diagnostic or Interventional Coronary Procedures. Circulation, 2015, 131, 2114-2119.	1.6	87
146	Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Journal of Cardiovascular Medicine, 2015, 16, 286-295.	1.5	2
147	Outcomes following primary percutaneous coronary intervention for unprotected left main-related ST-segment elevation myocardial infarction. Journal of Cardiovascular Medicine, 2015, 16, 163-169.	1.5	6
148	Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2015, 8, e171-e172.	2.9	5
149	TCT-517 Long term clinical outcome following Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-stent Restenosis: a Multicenter Italian Experience. Journal of the American College of Cardiology, 2015, 66, B211.	2.8	1
150	TCT-538 Clinical outcomes following percutaneous coronary intervention with Absorb BVS in patients with distal coronary artery disease. Results from the Italian RAI multicenter registry. Journal of the American College of Cardiology, 2015, 66, B220.	2.8	0
151	Everolimus-eluting stent versus bare-metal stent in elderly (â‰¥75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology, 2015, 179, 73-78.	1.7	17
152	â€œFull plastic jacketâ€• 18-month follow-up after implantation of multiple overlapping bioresorbable vascular scaffolds. EuroIntervention, 2015, 11, e1-e1.	3.2	2
153	Longâ€term clinical outcomes following drugâ€eluting stent implantation for unprotected distal trifurcation left main disease: The Milanâ€New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 83, 530-538.	1.7	16
154	Successful management of a huge thrombus in coronary aneurysmatic dilatation after failed mechanical thrombectomy during acute myocardial infarction. Journal of Cardiovascular Medicine, 2014, 15, 80-81.	1.5	6
155	Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. International Journal of Cardiology, 2014, 173, 513-514.	1.7	32
156	No more metallic cages: An attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel. International Journal of Cardiology, 2014, 172, 618-619.	1.7	9
157	The impact of main branch restenosis on long term mortality following drugâ€eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 84, 341-348.	1.7	18
158	Current and future perspectives on drug-eluting bioresorbable coronary scaffolds. Future Cardiology, 2014, 10, 409-420.	1.2	6
159	TCT-609 Comparison of one year outcomes in real world patients treated with a polymer free amphilimus eluting coronary stent versus second generation everolimus eluting stents. Journal of the American College of Cardiology, 2014, 64, B178.	2.8	0
160	Impact of renal dysfunction on long-term mortality in patients with unprotected left main disease: Milan and New-Tokyo (MITO) Registry. International Journal of Cardiology, 2014, 177, 1131-1133.	1.7	6
161	Guide-catheter extension system facilitated multiple bioresorbable vascular scaffolds (ABSORBÂ®) delivery in a very long and resistant coronary artery lesion. Cardiovascular Revascularization Medicine, 2014, 15, 117-120.	0.8	6
162	Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?. EuroIntervention, 2014, 10, 337-337.	3.2	2

#	Article	IF	Citations
163	The diabetic dilemma: which drug-eluting stent works best?. Minerva Cardioangiologica, 2014, 62, 39-57.	1.2	0
164	Directional atherectomy of a heavy calcified axillary artery stenosis inducing critical hand ischemia. Cardiovascular Intervention and Therapeutics, 2013, 28, 300-302.	2.3	7
165	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
166	Resultados a muy largo plazo tras la implantaciÃ³n de stents liberadores de fÃ¡rmacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. Revista Espanola De Cardiologia, 2013, 66, 24-33.	1.2	10
167	TCT-812 The Impact of Renal Function on Long-term Mortality in Unprotected Left Main Disease, Milan and New-Tokyo Registry. Journal of the American College of Cardiology, 2013, 62, B246.	2.8	0
168	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. Revista Espanola De Cardiologia (English Ed), 2013, 66, 24-33.	0.6	3
169	Impact of bifurcation technique on long-term clinical outcomes in 976 patients with distal unprotected left main coronary artery stenosis treated with drug-eluting stents; Milan and new-Tokyo registry. European Heart Journal, 2013, 34, P3998-P3998.	2.2	0
170	Long-term survival in patients undergoing drug-eluting stent PCI of the unprotected left main coronary artery according to renal function; Milan and New-Tokyo (MITO) registry. European Heart Journal, 2013, 34, P4813-P4813.	2.2	0
171	Current and new-generation transcatheter aortic valve devices: an update on emerging technologies. Expert Review of Cardiovascular Therapy, 2013, 11, 1393-1405.	1.5	10
172	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
173	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. EuroIntervention, 2013, 9, 809-816.	3.2	26
174	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. Circulation: Cardiovascular Interventions, 2012, 5, 491-498.	3.9	29
175	039â€...Outcomes following unprotected left main stenting with first vs second generation drug-eluting stents: the Milan experience. Heart, 2012, 98, A24.2-A24.	2.9	0
176	Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity scoreâ€“matched case-control study. American Heart Journal, 2012, 164, 910-917.	2.7	111
177	TCT-370 Outcomes According to Sex Following Unprotected Left Main Stenting With Drug-Eluting Stents: The Milan Experience. Journal of the American College of Cardiology, 2012, 60, B106.	2.8	0
178	TCT-701 Two Year Outcomes Following Unprotected Left Main Stenting with First- vs. New-Generation Drug-Eluting Stents: The FINE Registry. Journal of the American College of Cardiology, 2012, 60, B204.	2.8	0
179	TCT-709 Predictors of Main Branch Restenosis Following Drug-eluting Stent Implantation in Patients with De Novo Unprotected Distal Left Main Bifurcation Coronary Lesions: The MIlan and New-TOkyo (MITO) Registry. Journal of the American College of Cardiology, 2012, 60, B206.	2.8	0
180	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21

#	Article	IF	Citations
181	Kissing drug-eluting balloons for the treatment of unprotected distal left main bifurcation drug-eluting stent restenosis. Cardiovascular Revascularization Medicine, 2012, 13, 347-349.	0.8	4
182	Resolute italian study in all comers. Catheterization and Cardiovascular Interventions, 2012, 79, 567-574.	1.7	9
183	AS-170 Outcomes Following Unprotected Left Main Stenting with Newer Generation Drug-Eluting Stents: The Milan Experience. American Journal of Cardiology, 2012, 109, S85.	1.6	0
184	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
185	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43
186	Current and future drug-eluting coronary stent technology. Expert Review of Cardiovascular Therapy, 2011, 9, 485-503.	1.5	20
187	Sandwich Stenting to Treat an Ostial Left Main Narrowing Following Transcatheter Aortic Valve Implantation. Revista Espanola De Cardiologia (English Ed), 2011, 64, 1220-1222.	0.6	1
188	Scimitar syndrome. Journal of Cardiovascular Medicine, 2011, 12, 176-177.	1.5	2
189	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. American Journal of Cardiology, 2011, 108, 1055-1060.	1.6	19
190	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. Cardiovascular Revascularization Medicine, 2011, 12, 220-227.	0.8	10
191	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66
192	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62
193	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
194	Treatment of iatrogenic occlusive coronary dissections: a novel approach. EuroIntervention, 2011, 7, 106-111.	3.2	16
195	Percutaneous Unprotected Left Main Coronary Artery Interventions â€“ Updated Results and Current Recommendations. Interventional Cardiology Review, 2011, 6, 44.	1.6	0
196	Tools & Techniques: Left main coronary artery percutaneous coronary intervention. EuroIntervention, 2011, 6, 1020-1021.	3.2	1
197	A high dose of adenosine to induce transient asystole for valvuloplasty in patients undergoing transcatheter aortic valve implantation (TAVI): is it a valid alternative to rapid pacing? A prospective pilot study. Journal of Invasive Cardiology, 2011, 23, 467-71.	0.4	12
198	Stent Thrombosis and Duration of Dual Antiplatelet Therapy. Current Pharmaceutical Design, 2010, 16, 4052-4063.	1.9	7

#	Article	IF	Citations
199	Reply on anomalous left coronary artery origin from the pulmonary artery (ALCAPA): an unusual late presentation of Blandâ€“Garlandâ€“White syndrome. Journal of Cardiovascular Medicine, 2010, 11, 556.	1.5	0
200	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136
201	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
202	Prolonged Double Antiplatelet Therapy in a Cohort of â€œDe Novoâ€•Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
203	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. American Journal of Cardiology, 2010, 106, 1721-1727.	1.6	45
204	A new technique for vascular access management in transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 75, 784-793.	1.7	123
205	Coronary Left Main and Nonâ€Left Main Bifurcation Angles: How are the Angles Modified by Different Bifurcation Stenting Techniques?. Journal of Interventional Cardiology, 2010, 23, 382-393.	1.2	17
206	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
207	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
208	Long-Term Follow-Up on a Large Cohort of â€œFull-Metal Jacketâ€•Percutaneous Coronary Intervention Procedures. Circulation: Cardiovascular Interventions, 2009, 2, 416-422.	3.9	54
209	Broken heart syndrome: tako-tsubo cardiomyopathy. Cmaj, 2009, 180, 1033-1034.	2.0	5
210	Longâ€term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. European Journal of Heart Failure, 2009, 11, 581-587.	7.1	143
211	Defining a new standard for IVUS optimized drug eluting stent implantation: The PRAVIO study. Catheterization and Cardiovascular Interventions, 2009, 74, 348-356.	1.7	22
212	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1219-1226.	2.9	28
213	Anomalous left coronary artery origin from the pulmonary artery: an unusual late presentation of Blandâ€“Garlandâ€“White syndrome. Journal of Cardiovascular Medicine, 2009, 10, 719-721.	1.5	1
214	Malignant ST segment elevation. European Heart Journal, 2008, 29, 2448-2448.	2.2	1
215	Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 85-89.	0.6	2
216	SPECIES VARIATION IN ANTIBODY RESPONSE. The Australian Journal of Experimental Biology and Medical Science, 1969, 47, 689-699.	0.7	4